Scarica l'app Stockscreener
469.34
1.84%
-8.79
Dopo l'orario di chiusura:
470.28
0.94
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$478.13
Aprire:
$481.79
Volume 24 ore:
1.10M
Relative Volume:
0.76
Capitalizzazione di mercato:
$119.23B
Reddito:
$12.07B
Utile/perdita netta:
$3.95B
Rapporto P/E:
30.61
EPS:
15.3349
Flusso di cassa netto:
$3.19B
1 W Prestazione:
+2.77%
1M Prestazione:
-4.50%
6M Prestazione:
+18.96%
1 anno Prestazione:
-6.68%
Intervallo 1D:
$469.08
$486.66
Intervallo di 1 settimana:
$450.78
$507.92
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Vertex Pharmaceuticals (VRTX)'s IgA Nephropathy Win Means For Its Next Major Franchise Potential - simplywall.st
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake - National Today
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup - ChartMill
2 Factors to Consider Investing in VRTX and 1 Reason to Remain Careful - Bitget
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Vertex Pharmaceuticals (VRTX) Pricing In Too Much Optimism After Recent Share Gains? - simplywall.st
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex Pharmaceuticals (VRTX) Sees Target Price Raised by Truist Securities | VRTX Stock News - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Acquires 14,706 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CreativeOne Wealth LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma (NASDAQ:VRTX) Market Focus Builds Across Nasdaq Index - Kalkine Media
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo! Finance Canada
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Vertex Pharmaceuticals Shares Sold by Schroder Investment Management - National Today
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Schroder Investment Management Group - MarketBeat
Van ECK Associates Corp Has $58.38 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex preps FDA filing for IgAN drug after phase 3 readout - pharmaphorum
S&P 500 Dips 0.21% as Vertex Pharmaceuticals Soars 8.31% Amid Market Struggles - Markets Mojo
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Richard Bernstein Advisors LLC Sells 4,059 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
DE Burlo Group Inc. Sells 43,740 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Kidney Trial Success Opens Door To New Autoimmune Franchise - simplywall.st
Blair William & Co. IL Reduces Vertex Pharmaceuticals Stake - National Today
Bank of Montreal Boosts Vertex Pharmaceuticals Holdings by 15.5% - National Today
Vertex Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating - Investor's Business Daily
Bank of Montreal Can Has $164.28 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Narrow-Moat Vertex's Positive Data for Povetacicept Support Diversification Beyond Core CF Franchise - Morningstar
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Yahoo Finance
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug - Investor's Business Daily
Vertex Pharmaceuticals Stock Jumps with Positive Drug Pipeline News - timothysykes.com
Vertex Pharmaceuticals Hits Milestone with Povetacicept Data, Shares Surge - StocksToTrade
These Stocks Are Today’s Movers: BioNTech, NIO, Centene, Vertex, Paramount, Rivian, Occidental, and More - Barron's
Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. - Barron's
Vertex Pharmaceuticals (VRTX) Receives Rating Update and Price T - GuruFocus
Key facts: Vertex Pharmaceuticals reports positive trial results; firms raise price targets - TradingView
Here’s Why Vertex Pharmaceuticals Stock (VRTX) Is Up 10% Today - TipRanks
Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition - MedCity News
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send? - TradingKey
Vertex Pharma Stock Rises on IgA Nephropathy Drug Trial Success | 2026News and Statistics - IndexBox
Vertex to seek approval of IgAN drug after Phase III success - Clinical Trials Arena
Vertex Pharmaceuticals Soars on Promising Phase 3 Trial Results for Povetacicept - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley - MarketBeat
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study - Finviz
This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia
Oil Crashes 10%, Stocks Rebound On Trump End-Of-War Signals: What's Moving Markets Tuesday? - Benzinga
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):